Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 30, 2024 08:00 ET | Source: ProSomnus Sleep Technologies, Inc.

ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA

ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
January 29, 2024 08:00 ET | Source: ProSomnus Sleep Technologies, Inc.

ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
November 29, 2023 13:40 ET | Source: Incannex Healthcare

Incannex Healthcare Announces Completion of its Redomiciliation to the United States

MELBOURNE, Australia and NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ: IXHL) is pleased to announce that its previously announced transaction to redomicile Incannex...
November 10, 2023 05:46 ET | Source: The Insight Partners

Americas Sleep Apnea Market Worth $4.10 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners

Pune, India, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Sleep apnea is a potentially serious sleep disorder where breathing repeatedly stops and starts. Such a condition prevents the patient's body from...
October 18, 2023 08:18 ET | Source: The Insight Partners

Sleep Apnea Implants Market Worth $803.26 Million by 2030 - Exclusive Report by The Insight Partners

Pune, India, Oct. 18, 2023 (GLOBE NEWSWIRE) -- North America accounted for the largest share of the global sleep apnea implants market in 2022. The North America sleep apnea implants market has...
October 18, 2023 08:00 ET | Source: Apnimed, Inc.

Apnimed to Present Review of Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
October 11, 2023 08:00 ET | Source: Apnimed, Inc.

Apnimed to Participate in Upcoming October Investor Conferences

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
October 10, 2023 08:30 ET | Source: Apnimed, Inc.

American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea

CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
October 02, 2023 08:00 ET | Source: Apnimed, Inc.

Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors

Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
September 21, 2023 08:30 ET | Source: ProSomnus Sleep Technologies, Inc.

ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations

PLEASANTON, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced...